Published in Ann Surg Oncol on April 12, 2004
Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology. Ann Surg (2007) 1.23
A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities. Ann Surg Oncol (2011) 0.89
Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety. Oncologist (2010) 0.89
Toxicity and morbility after isolated lower limb perfusion in 242 chemo-hyperthermal treatments for cutaneous melanoma: the experience of the Tuscan Reference Centre. J Exp Clin Cancer Res (2008) 0.81
Where are we going with regional therapy for melanoma? Ann Surg Oncol (2004) 0.75
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med (2006) 15.64
Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med (2014) 10.69
Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst (2010) 5.23
Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol (2009) 4.32
Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg (2005) 3.80
Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst (2006) 3.17
The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol (2010) 3.02
Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol (2011) 2.62
Reliability and safety of current dynamic sentinel node biopsy for penile carcinoma. Eur Urol (2007) 2.44
The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol (2005) 2.41
Anatomical mapping of lymphatic drainage in penile carcinoma with SPECT-CT: implications for the extent of inguinal lymph node dissection. Eur Urol (2008) 2.19
TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist (2006) 2.17
Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol (2013) 2.08
Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol (2006) 2.00
Ultrasonography and fine-needle aspiration cytology can spare breast cancer patients unnecessary sentinel lymph node biopsy. Ann Surg Oncol (2006) 1.95
The yield of SPECT/CT for anatomical lymphatic mapping in patients with melanoma. Ann Surg Oncol (2009) 1.93
Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials. J Clin Oncol (2012) 1.93
Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol (2012) 1.92
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer (2011) 1.78
Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol (2005) 1.70
EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging (2009) 1.68
Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J Clin Oncol (2003) 1.68
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol (2013) 1.67
Improved intratumoral nanoparticle extravasation and penetration by mild hyperthermia. J Control Release (2013) 1.66
Is the clinical risk score for patients with colorectal liver metastases still useable in the era of effective neoadjuvant chemotherapy? Ann Surg Oncol (2011) 1.63
20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters. Ann Surg Oncol (2011) 1.60
Nodal staging in penile carcinoma by dynamic sentinel node biopsy after previous therapeutic primary tumour resection. Eur Urol (2010) 1.55
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer (2005) 1.55
Comparing the hybrid fluorescent-radioactive tracer indocyanine green-99mTc-nanocolloid with 99mTc-nanocolloid for sentinel node identification: a validation study using lymphoscintigraphy and SPECT/CT. J Nucl Med (2012) 1.53
Lymphatic drainage patterns from the breast. Ann Surg (2004) 1.53
Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients. J Surg Oncol (2011) 1.48
Comparison of three micromorphometric pathology classifications of melanoma metastases in the sentinel node. Ann Surg (2009) 1.44
Radiotherapy for soft tissue sarcomas after isolated limb perfusion and surgical resection: essential for local control in all patients? Ann Surg Oncol (2010) 1.44
Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated. Psychosomatics (2008) 1.44
Size of metastasis in the sentinel node predicts additional nodal involvement in penile carcinoma. J Urol (2006) 1.43
Lymphatic mapping in patients with breast carcinoma: reproducibility of lymphoscintigraphic results. Radiology (2003) 1.43
Clinical implications of sentinel nodes outside the axilla and internal mammary chain in patients with breast cancer. J Surg Oncol (2006) 1.43
Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J Invest Dermatol (2010) 1.42
Feasibility of sentinel node lymphoscintigraphy in stage I testicular cancer. Eur J Nucl Med Mol Imaging (2002) 1.42
Significance of serum S-100B in melanoma patients before and after sentinel node biopsy. J Surg Oncol (2005) 1.40
Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol (2005) 1.36
Visualization of tumor blockage and rerouting of lymphatic drainage in penile cancer patients by use of SPECT/CT. J Nucl Med (2009) 1.33
Feasibility of sentinel node biopsy in head and neck melanoma using a hybrid radioactive and fluorescent tracer. Ann Surg Oncol (2011) 1.25
Should the hunt for internal mammary chain sentinel nodes begin? An evaluation of 150 breast cancer patients. Ann Surg Oncol (2003) 1.20
Differential effects of matrix and growth factors on endothelial and fibroblast motility: application of a modified cell migration assay. J Cell Biochem (2006) 1.20
Triggered content release from optimized stealth thermosensitive liposomes using mild hyperthermia. J Control Release (2010) 1.19
Prognosis of primary mucosal penile melanoma: a series of 19 Dutch patients and 47 patients from the literature. Urology (2007) 1.18
SPECT/CT for preoperative sentinel node localization. J Surg Oncol (2010) 1.17
LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer (2009) 1.15
Redefining the role of interferon in the treatment of malignant diseases. Eur J Cancer (2009) 1.15
Two-center evaluation of dynamic sentinel node biopsy for squamous cell carcinoma of the penis. J Clin Oncol (2009) 1.11
Review and evaluation of sentinel node procedures in 250 melanoma patients with a median follow-up of 6 years. Ann Surg Oncol (2003) 1.11
Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response. Cancer Res (2007) 1.11
Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J Natl Cancer Inst (2009) 1.11
The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol (2003) 1.10
Impact of volume and location of irradiated rectum wall on rectal blood loss after radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys (2004) 1.09
Laparoscopic partial cholecystectomy for the difficult gallbladder: a systematic review. Surg Endosc (2012) 1.08
Hyperthermia and thermosensitive liposomes for improved delivery of chemotherapeutic drugs to solid tumors. Pharm Res (2010) 1.08
Assessment of lymphatic drainage patterns and implications for the extent of neck dissection in head and neck melanoma patients. J Surg Oncol (2011) 1.07
The additional value of SPECT/CT in lymphatic mapping in breast cancer and melanoma. J Nucl Med (2007) 1.06
Mild hyperthermia triggered doxorubicin release from optimized stealth thermosensitive liposomes improves intratumoral drug delivery and efficacy. J Control Release (2013) 1.05
Comparison of imaging strategies with conditional contrast-enhanced CT and unenhanced MR imaging in patients suspected of having appendicitis: a multicenter diagnostic performance study. Radiology (2013) 1.04
A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein. J Immunol (2003) 1.04
Epidemiological evidence that UVA radiation is involved in the genesis of cutaneous melanoma. Curr Opin Oncol (2011) 1.04
Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer (2006) 1.03
Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site. Ann Surg Oncol (2011) 1.03
Hereditary breast cancer growth rates and its impact on screening policy. Eur J Cancer (2005) 1.03
The Hybrid SPECT/CT as an additional lymphatic mapping tool in patients with breast cancer. World J Surg (2008) 1.02
Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies. Eur J Cancer (2013) 1.01
Rotterdam Criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)-guided fine-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma? J Clin Oncol (2009) 1.01
The biology behind prognostic factors of cutaneous melanoma. Curr Opin Oncol (2010) 1.01
Outcome of microscopic incomplete resection (R1) of colorectal liver metastases in the era of neoadjuvant chemotherapy. Ann Surg Oncol (2011) 1.01
Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991. J Clin Oncol (2010) 1.00
SPECT-CT and real-time intraoperative imaging: new tools for sentinel node localization and radioguided surgery? Eur J Nucl Med Mol Imaging (2009) 1.00
Additional axillary metastases and stage migration in breast cancer patients with micrometastases or submicrometastases in sentinel lymph nodes. Cancer (2006) 1.00
Immunologic functions as prognostic indicators in melanoma. Mol Oncol (2011) 1.00
Preoperative radiotherapy improves outcome in recurrent rectal cancer. Dis Colon Rectum (2005) 0.99
Lymphatic drainage patterns from the treated breast. Ann Surg Oncol (2009) 0.99
Evaluation of a clinically applicable post-surgical classification system for primary retroperitoneal soft-tissue sarcoma. Ann Surg Oncol (2004) 0.98